Cyclobenzaprine (hydrochloride)

Cyclobenzaprine (MK130) hydrochloride is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine hydrochloride acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Cyclobenzaprine hydrochloride also possesses antiparasitic activity. Cyclobenzaprine hydrochloride holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases[1][2][3][4][5].

Product Specifications

CAS Number

[6202-23-9]

Product Name Alternative

MK130 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H301, H312+H332

Target

5-HT Receptor; Parasite

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Cyclobenzaprine-hydrochloride.html

Concentration

10mM

Purity

99.96

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

CN(C)CC/C=C1C2=CC=CC=C2C=CC3=CC=CC=C\13.Cl

Molecular Formula

C20H22ClN

Molecular Weight

311.85

Precautions

H301, H312+H332

References & Citations

[3]Borenstein D G & Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials[J]. Clinical therapeutics, 2003, 25 (4) : 1056-1073.|[4]Share N N, et al. Cyclobenzaprine: a novel centrally acting skeletal muscle relaxant[J]. Neuropharmacology, 1975, 14 (9) : 675-684.|[5]Cunha-Júnior EF, et al. Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice. PLoS Negl Trop Dis. 2017 Jan 3;11 (1) :e0005281. |[1]Kobayashi, H., Y. Hasegawa, and H. Ono, Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol, 1996. 311 (1) : p. 29-35.|[2]Honda, M., T. Nishida, and H. Ono, Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT (2) receptors. Eur J Pharmacol, 2003. 458 (1-2) : p. 91-9.